{"id":64648,"date":"2026-05-07T14:40:40","date_gmt":"2026-05-07T06:40:40","guid":{"rendered":"https:\/\/flcube.com\/?p=64648"},"modified":"2026-05-07T14:40:41","modified_gmt":"2026-05-07T06:40:41","slug":"bayer-to-acquire-perfuse-therapeutics-for-up-to-2-45-billion-expands-ophthalmology-portfolio-with-phase-2-endothelin-receptor-antagonist","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64648","title":{"rendered":"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist"},"content":{"rendered":"\n<p><strong>Bayer AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) and <strong>Perfuse Therapeutics Inc.<\/strong> announced on <strong>May 6, 2026<\/strong>, a definitive agreement under which <strong>Bayer will fully acquire Perfuse Therapeutics<\/strong>, a biopharmaceutical company pioneering <strong>transformational research into ischemia-induced ocular diseases<\/strong>. The transaction, valued at up to <strong>USD 2.45 billion<\/strong>, provides Bayer with full rights to <strong>PER-001<\/strong>, a <strong>small molecule endothelin receptor antagonist<\/strong> currently in <strong>Phase 2 clinical development<\/strong> for <strong>glaucoma and diabetic retinopathy (DR)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-details\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Value<\/th><th>Structure<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Potential Value<\/strong><\/td><td>USD 2.45 billion<\/td><td>Contingent on achievement of milestones<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 300 million<\/td><td>Cash payment upon closing<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD 2.15 billion<\/td><td>Development, regulatory, and commercial success-based payments<\/td><\/tr><tr><td><strong>Target Asset<\/strong><\/td><td>PER-001<\/td><td>Small molecule endothelin receptor antagonist<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase 2<\/td><td>For glaucoma and diabetic retinopathy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The acquisition represents a strategic expansion of Bayer&#8217;s <strong>ophthalmology franchise<\/strong>, adding a novel mechanism of action targeting the underlying <strong>ischemic pathology<\/strong> in leading causes of vision loss.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-profile-amp-therapeutic-innovation\">Asset Profile &amp; Therapeutic Innovation<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-per-001-endothelin-receptor-antagonist\">PER-001 \u2013 Endothelin Receptor Antagonist<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Targets <strong>endothelin receptors<\/strong> involved in vascular dysregulation and ischemia in ocular tissues<\/li>\n\n\n\n<li><strong>Indications<\/strong>:<\/li>\n\n\n\n<li><strong>Glaucoma<\/strong>: Addresses vascular components contributing to optic nerve damage beyond intraocular pressure reduction<\/li>\n\n\n\n<li><strong>Diabetic Retinopathy (DR)<\/strong>: Targets ischemia-driven pathological angiogenesis and vascular leakage<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Novel approach focusing on <strong>ischemia-induced mechanisms<\/strong> rather than conventional pressure-lowering or anti-VEGF strategies<\/li>\n\n\n\n<li><strong>Development Status<\/strong>: Currently in <strong>Phase 2 clinical trials<\/strong> with data expected to inform pivotal study design<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scientific-rationale\">Scientific Rationale<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ischemia as Common Pathway<\/strong>: Both glaucoma and DR involve <strong>chronic ocular ischemia<\/strong> leading to progressive vision loss<\/li>\n\n\n\n<li><strong>Endothelin System Role<\/strong>: Endothelin-1 is upregulated in ischemic retinal and optic nerve tissues, contributing to vasoconstriction, inflammation, and fibrosis<\/li>\n\n\n\n<li><strong>Therapeutic Potential<\/strong>: PER-001 may provide <strong>neuroprotective and vasoprotective effects<\/strong> addressing root causes rather than downstream symptoms<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-opportunity\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Market Size<\/th><th>Unmet Need<\/th><th>Bayer&#8217;s Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Glaucoma<\/strong><\/td><td>Global market &gt;$6 billion annually<\/td><td>Limited options beyond IOP-lowering; need for neuroprotection<\/td><td>Complements existing Eylea franchise; potential first-in-class mechanism<\/td><\/tr><tr><td><strong>Diabetic Retinopathy<\/strong><\/td><td>Affects ~100 million globally; growing with diabetes epidemic<\/td><td>Anti-VEGF limitations; need for ischemia-targeting approaches<\/td><td>Expands beyond current anti-VEGF dominance into novel pathways<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-benefits-for-bayer\">Strategic Benefits for Bayer<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification<\/strong>: Adds <strong>first-in-class mechanism<\/strong> to ophthalmology portfolio beyond established anti-VEGF therapies<\/li>\n\n\n\n<li><strong>Dual-Indication Potential<\/strong>: Single asset addresses two major causes of blindness with overlapping pathophysiology<\/li>\n\n\n\n<li><strong>Innovation Leadership<\/strong>: Positions Bayer at forefront of <strong>ischemia-targeting ophthalmic therapeutics<\/strong>, a emerging therapeutic paradigm<\/li>\n\n\n\n<li><strong>Commercial Synergies<\/strong>: Leverages existing <strong>ophthalmology commercial infrastructure<\/strong> and physician relationships<\/li>\n<\/ul>\n\n\n\n<p>The acquisition reflects Bayer&#8217;s commitment to <strong>ophthalmic innovation<\/strong> and addresses significant unmet needs in diseases affecting hundreds of millions of patients worldwide. With diabetes prevalence continuing to rise globally and aging populations increasing glaucoma incidence, the market opportunity for effective ischemia-targeting therapies is substantial.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding acquisition terms, clinical development, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, and integration challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[269,967,44,4726],"class_list":["post-64648","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-bayer","tag-etr-bayn","tag-ophthalmology","tag-perfuse-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into ischemia-induced ocular diseases. The transaction, valued at up to USD 2.45 billion, provides Bayer with full rights to PER-001, a small molecule endothelin receptor antagonist currently in Phase 2 clinical development for glaucoma and diabetic retinopathy (DR).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64648\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into ischemia-induced ocular diseases. The transaction, valued at up to USD 2.45 billion, provides Bayer with full rights to PER-001, a small molecule endothelin receptor antagonist currently in Phase 2 clinical development for glaucoma and diabetic retinopathy (DR).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64648\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T06:40:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-07T06:40:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64648#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64648\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist\",\"datePublished\":\"2026-05-07T06:40:40+00:00\",\"dateModified\":\"2026-05-07T06:40:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64648\"},\"wordCount\":480,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Ophthalmology\",\"Perfuse Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64648#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64648\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64648\",\"name\":\"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-07T06:40:40+00:00\",\"dateModified\":\"2026-05-07T06:40:41+00:00\",\"description\":\"Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into ischemia-induced ocular diseases. The transaction, valued at up to USD 2.45 billion, provides Bayer with full rights to PER-001, a small molecule endothelin receptor antagonist currently in Phase 2 clinical development for glaucoma and diabetic retinopathy (DR).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64648#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64648\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64648#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into ischemia-induced ocular diseases. The transaction, valued at up to USD 2.45 billion, provides Bayer with full rights to PER-001, a small molecule endothelin receptor antagonist currently in Phase 2 clinical development for glaucoma and diabetic retinopathy (DR).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64648","og_locale":"en_US","og_type":"article","og_title":"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist","og_description":"Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into ischemia-induced ocular diseases. The transaction, valued at up to USD 2.45 billion, provides Bayer with full rights to PER-001, a small molecule endothelin receptor antagonist currently in Phase 2 clinical development for glaucoma and diabetic retinopathy (DR).","og_url":"https:\/\/flcube.com\/?p=64648","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-07T06:40:40+00:00","article_modified_time":"2026-05-07T06:40:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64648#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64648"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist","datePublished":"2026-05-07T06:40:40+00:00","dateModified":"2026-05-07T06:40:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64648"},"wordCount":480,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bayer","ETR: BAYN","Ophthalmology","Perfuse Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64648#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64648","url":"https:\/\/flcube.com\/?p=64648","name":"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-07T06:40:40+00:00","dateModified":"2026-05-07T06:40:41+00:00","description":"Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into ischemia-induced ocular diseases. The transaction, valued at up to USD 2.45 billion, provides Bayer with full rights to PER-001, a small molecule endothelin receptor antagonist currently in Phase 2 clinical development for glaucoma and diabetic retinopathy (DR).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64648#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64648"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64648#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion \u2013 Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64648"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64648\/revisions"}],"predecessor-version":[{"id":64649,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64648\/revisions\/64649"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}